Filing Details
- Accession Number:
- 0001144204-13-051491
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-09-18 21:31:48
- Reporting Period:
- 2013-09-17
- Filing Date:
- 2013-09-18
- Accepted Time:
- 2013-09-18 21:31:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559569 | Mark Pruzanski | C/O Intercept Pharmaceuticals, Inc. 18 Desbrosses St. New York NY 10013 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-09-17 | 12,500 | $9.82 | 414,532 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-09-17 | 12,500 | $9.82 | 427,032 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-09-17 | 25,000 | $52.00 | 402,032 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Options to Purchase Common Stock | Disposition | 2013-09-17 | 12,500 | $0.00 | 12,500 | $9.82 |
Common Stock | Options to Purchase Common Stock | Disposition | 2013-09-17 | 12,500 | $0.00 | 12,500 | $9.82 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2016-07-18 | No | 4 | M | Direct | |
20,911 | 2018-09-18 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 22, 2013.
- All shares underlying this option have fully vested.